Antibacterial Agents TRIZ Cases

A moisturizing antibacterial composition disperses oil droplets sized 50 to 2500 micrometers within an aqueous alcohol base.

Replacing large C1q domains with TNF-derived trimerization modules reduces molecular weight while maintaining stability and activity.

Specific monoclonal antibodies neutralize Clostridium difficile TcdA and TcdB toxins, reducing disease severity despite high toxin concentrations.

Alkylthiazole carbamate derivatives address insufficient inhibitory activity by optimizing molecular parameters and segmentation.

Purified galactolipids from Crassocephalum rabens reduce liver injury markers and inflammation through targeted extraction.

Attenuated superantigen toxoids fused into a single multivalent oligopeptide construct to induce broad neutralizing antibody responses.

Screened Lactobacillus johnsonii strain eliminates harmful D-lactic acid while maintaining infant safety and shelf stability.

Novel triazole compounds inhibit acetyl-CoA carboxylase to treat obesity and act as broad-spectrum antifungal agents.

Streptococcus and Lactobacillus combinations overcome antibiotic resistance by producing bacteriocins that kill Staphylococcus strains.

Bacteriophage SP-1 selectively eliminates Salmonella without harming beneficial flora, avoiding antibiotic resistance side effects.

Passing carbon dioxide enriched air through liquid culture medium during exponential growth phase to stimulate RTX-toxin production.

Cashew nut shell liquid components replace antibiotics to reduce colibacillosis incidence while maintaining productivity.

Moderate-level aliphatic alcohol combined with cationic substrate binding agents sustains residual antimicrobial activity while preventing skin irritation.

Optimized substituted piperidine structures balance potent HDM2 inhibition with minimal cytochrome P450 3A4 enzyme interference.

5-Aminosalicylic acid derivatives scavenge superoxide radicals, improving DNA replication fidelity and reducing mutation rates in colorectal cancer prevention.

Metabolic priming with carbon sources and electron acceptors overcomes density-dependent persistence in high-density bacterial populations.

Multi-stage solvent extraction of processed herbs improves antioxidant reliability while managing manufacturing complexity.

Formula I heterocyclic compounds overcome bacterial resistance by varying substituent groups on the core structure to maintain antimicrobial effectiveness.

Substituted triazole compounds inhibit heat shock protein 90 activity to destabilize and degrade client proteins in cancer cells.

A cellular energy inhibitor composition stabilizes the active compound using sugar alcohol to deplete cancer cell metabolism.

Composite microparticles bearing specific ligands resolve the contradiction between active agent release efficiency and selective delivery to macrophages.

Halogenated alkyl groups on the pyrazolonaphthyridine core enhance PDE IV selectivity while avoiding central nervous system side effects.

R-G-Cysteic Acid peptides induce posterior vitreous detachment and down-regulate VEGF receptors, reducing injection frequency for neovascular eye diseases.

Aminoglycoside coacervates initiate lipid bilayer formation around active agents to achieve high entrapment efficiencies.

Human monoclonal antibodies bind pneumococcal antigens PhtD and PspA to inhibit Streptococcus pneumoniae infection.

Hydroxyl anilino thieno pyrimidine compounds inhibit c-Src and DDR tyrosine kinases.

Direct embryo injection of immunogenic compositions induces protective immune responses, eliminating antibiotic resistance risks.

Varying the carbon linker length in an oxoadenine compound resolves selectivity and potency trade-offs for TLR7/8 activation.

Combining silver, zinc oxide, and hyaluronic acid provides comprehensive antimicrobial and anti-inflammatory action for mucous membrane diseases.

Phase equilibration transforms amorphous fluorinated indole acid into stable crystalline Form 3, resolving solubility and stability bottlenecks.

Ultrafiltration membranes remove colored impurities from macrolide solutions, resolving purity and color stability trade-offs.

Targeting linear epitope RNSKYPQD overcomes species variability and low efficacy of prior antagonists.

Poloxamer micelles encapsulate cationic steroidal antimicrobial compounds to stabilize the formulation and reduce molecular agglomeration.

Segmenting targeting from TNF to its receptor reduces immune suppression while maintaining therapeutic efficacy in chronic inflammatory diseases.

Diazepane-acetamide derivatives selectively inhibit 11β-HSD1, reducing cortisol levels while avoiding side effects from non-specific inhibition of 11β-HSD2.

Novel single domain antibodies bind tetanus neurotoxin with high affinity, resolving low solubility and cost issues of polyclonal antitoxins.

Heteroaryl compounds act as potent MEK inhibitors to target cancer pathways with high specificity.

Live non-pathogenic Mycoplasma bovis bacteria induce protective immune responses in cattle without adjuvants.

Scheduling vaccine administration relative to soluble CTLA4 molecule serum levels optimizes antibody production in immunocompromised subjects.

Copolymerizing glycine and agmatine with N,N-methylenebisacrylamide yields polyamidoamines with strong antimicrobial activity.

Porous three-dimensional composite material binds microbicidal agents to prevent elution, maintaining oxygen supply for wound healing.

Polymer formulations eliminate harsh chemical solvents by allowing graffiti removal with water and soap while maintaining long-lasting surface protection.

Retinoic acid and histone deacetylase inhibitors in culture media resolve the trade-off between viral titer and process complexity, sustaining high yields.

MW0118 antibodies bind bacterial surface proteins to block host tissue attachment, addressing antibiotic resistance in MRSA infections.

Alpha-hydroxy cycloalkanecarboxamide derivatives target bradykinin B1 receptors to overcome the lack of selective antagonists for pain management.

N-containing heterocyclic compounds resolve selectivity challenges by targeting unique active site features of JAK and Aurora kinases.